BR112019007796A2 - construção de vacina e seus usos contra infecções causadas por staphylococcus - Google Patents
construção de vacina e seus usos contra infecções causadas por staphylococcusInfo
- Publication number
- BR112019007796A2 BR112019007796A2 BR112019007796A BR112019007796A BR112019007796A2 BR 112019007796 A2 BR112019007796 A2 BR 112019007796A2 BR 112019007796 A BR112019007796 A BR 112019007796A BR 112019007796 A BR112019007796 A BR 112019007796A BR 112019007796 A2 BR112019007796 A2 BR 112019007796A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptide
- seq
- amino acid
- acid sequence
- absent
- Prior art date
Links
- 241000191940 Staphylococcus Species 0.000 title abstract 2
- 238000010276 construction Methods 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 22
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 22
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 22
- 150000001413 amino acids Chemical class 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 230000004927 fusion Effects 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000344863 Staphylococcus aureus subsp. aureus COL Species 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
construção de vacina e seus usos contra infecções causadas por staphylococcus. é fornecida uma construção de fusão da fórmula (i): x-a-ligante-b-z (i) em que: (1) a e b são idênticos ou diferentes e são independentemente: (a) um polipeptídeo compreendendo um polipeptídeo sacol0029 como apresentado em qualquer uma das sequências representadas na fig. 24 (id seq nº.: 5 e 121 a 131), um polipeptídeo sacol0264 (id seq nº: 185), um polipeptídeo sacol0442 como apresentado em qualquer uma das sequências representadas na fig. 22d (id seq nº.: 29 e 82 a 92), um polipeptídeo sacol0718 (id seq nº: 186), um polipeptídeo sacol0720 como apresentado em qualquer uma das sequências representadas nas figs. 23i-j (id seq nº.: 11 e 109 a 120), um polipeptídeo sacol1353 (id seq nº: 187), um polipeptídeo sacol1416 (id seq nº.: 188), um polipeptídeo sacol1611 (id seq nº.: 189), um polipeptídeo sacol1867 como apresentado em qualquer uma das sequências representadas na fig. 25d (id seq nº.: 152 a 164), um polipeptídeo sacol1912 (id seq nº: 43), um polipeptídeo sacol1944 (id seq nº.: 190), um polipeptídeo sacol2144 (id seq nº.: 191), um polipeptídeo sacol2365 (id seq nº.: 192), um polipeptídeo sacol2385 (id seq nº.: 50) ou um polipeptídeo sacol2599 (id seq nº.: 193), com base na nomenclatura genética do genoma de staphylococcus aureus col (sacol) estabelecido na ncbi reference sequence nc_002951.2; (b) um polipeptídeo codificado por um gene de um mesmo operão como um gene que codifica o polipeptídio de (a); (c) um polipeptídio compreendendo um fragmento imunogênico de pelo menos 13 aminoácidos consecutivos de (a) ou (b); (d) um polipeptídeo compreendendo uma sequência de aminoácidos pelo menos 60% globalmente idêntica à sequência do polipeptídeo de qualquer um de (a) a (c); ou (e) um polipeptídio compreendendo uma variante imunogênica compreendendo pelo menos 13 aminoácidos consecutivos de qualquer um de (a) a (c); (2) o ligante é uma sequência de aminoácidos de pelo menos um aminoácido ou está ausente; (3) x está ausente ou é uma sequência de aminoácidos de pelo menos um aminoácido; e (4) z está ausente ou é uma sequência de aminoácidos de pelo menos um aminoácido. também são fornecidas composições e kits que compreendem a fusão e os usos dessas fusões, composições e kits.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411120P | 2016-10-21 | 2016-10-21 | |
| PCT/CA2017/051253 WO2018072031A1 (en) | 2016-10-21 | 2017-10-20 | Vaccine constructs and uses thereof against staphylococcus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019007796A2 true BR112019007796A2 (pt) | 2019-09-03 |
Family
ID=62018642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019007796A BR112019007796A2 (pt) | 2016-10-21 | 2017-10-20 | construção de vacina e seus usos contra infecções causadas por staphylococcus |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11324815B2 (pt) |
| EP (1) | EP3529260A4 (pt) |
| JP (2) | JP7181208B2 (pt) |
| KR (1) | KR20190082229A (pt) |
| CN (1) | CN109843910A (pt) |
| AR (1) | AR109847A1 (pt) |
| AU (2) | AU2017346974B2 (pt) |
| BR (1) | BR112019007796A2 (pt) |
| CA (1) | CA3037070A1 (pt) |
| CL (1) | CL2019001048A1 (pt) |
| CO (1) | CO2019005169A2 (pt) |
| CR (1) | CR20190249A (pt) |
| DO (1) | DOP2019000102A (pt) |
| IL (1) | IL265869A (pt) |
| MX (2) | MX2019004539A (pt) |
| MY (1) | MY195369A (pt) |
| NZ (1) | NZ751880A (pt) |
| PE (1) | PE20191320A1 (pt) |
| PH (1) | PH12019500843A1 (pt) |
| RU (2) | RU2022100889A (pt) |
| SG (2) | SG11201901483QA (pt) |
| TW (1) | TW201819402A (pt) |
| UY (1) | UY37448A (pt) |
| WO (1) | WO2018072031A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220185852A1 (en) * | 2020-12-11 | 2022-06-16 | Bayer Animal Health Gmbh | Methods and compositions for improved production of an antigen for use in an s. aureus vaccine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1288774C (en) | 1985-01-07 | 1991-09-10 | Deborah A. Eppstein | 1,2-dialkoxy-w-trialkylammonium cationic surfactants |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US7060458B1 (en) | 1997-08-14 | 2006-06-13 | Wyeth | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6380370B1 (en) | 1997-08-14 | 2002-04-30 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics |
| US6833134B2 (en) | 2000-06-12 | 2004-12-21 | University Of Saskacthewan | Immunization of dairy cattle with GapC protein against Streptococcus infection |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| AU2003295520B8 (en) | 2002-11-12 | 2011-05-19 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for Staphylococcal infections |
| CN1569893A (zh) | 2003-07-21 | 2005-01-26 | 中国人民解放军军事医学科学院基础医学研究所 | 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途 |
| RU2419628C2 (ru) * | 2004-09-22 | 2011-05-27 | ГлаксоСмитКлайн Байолоджикалз с.а. | Иммуногенная композиция для применения в вакцинации против стафилококков |
| EP2340848A3 (en) * | 2004-10-21 | 2011-09-14 | Wyeth LLC | Immunogenic compositions of Staphylococcus epidermidis polypeptide and polynucleotide antigens |
| WO2006059846A1 (en) | 2004-12-01 | 2006-06-08 | Lg Life Sciences, Ltd. | Formulation of sec1 mutated protein and method for formulation of the same |
| WO2008152447A2 (en) | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| NZ614557A (en) * | 2009-03-23 | 2015-03-27 | Epitopix Llc | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use |
| CN109248313B (zh) * | 2009-04-14 | 2023-01-17 | 葛兰素史密丝克莱恩生物有限公司 | 用于免疫接种以抵御金黄色葡萄球菌的组合物 |
| PT2547361T (pt) | 2010-03-17 | 2020-12-07 | Socpra Sciences Et Genie Sec | Componentes de vacina bacteriana de staphylococcus aureus e suas utilizações |
| EP3403669B1 (en) | 2011-06-19 | 2020-07-15 | New York University | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
-
2017
- 2017-10-20 SG SG11201901483QA patent/SG11201901483QA/en unknown
- 2017-10-20 CA CA3037070A patent/CA3037070A1/en active Pending
- 2017-10-20 JP JP2019542759A patent/JP7181208B2/ja active Active
- 2017-10-20 KR KR1020197014191A patent/KR20190082229A/ko active IP Right Grant
- 2017-10-20 PE PE2019000844A patent/PE20191320A1/es unknown
- 2017-10-20 AR ARP170102922A patent/AR109847A1/es unknown
- 2017-10-20 US US16/337,457 patent/US11324815B2/en active Active
- 2017-10-20 RU RU2022100889A patent/RU2022100889A/ru unknown
- 2017-10-20 AU AU2017346974A patent/AU2017346974B2/en not_active Ceased
- 2017-10-20 CR CR20190249A patent/CR20190249A/es unknown
- 2017-10-20 BR BR112019007796A patent/BR112019007796A2/pt unknown
- 2017-10-20 UY UY0001037448A patent/UY37448A/es unknown
- 2017-10-20 CN CN201780064991.1A patent/CN109843910A/zh active Pending
- 2017-10-20 EP EP17863203.0A patent/EP3529260A4/en active Pending
- 2017-10-20 NZ NZ751880A patent/NZ751880A/en unknown
- 2017-10-20 MY MYPI2019002159A patent/MY195369A/en unknown
- 2017-10-20 WO PCT/CA2017/051253 patent/WO2018072031A1/en unknown
- 2017-10-20 TW TW106136089A patent/TW201819402A/zh unknown
- 2017-10-20 MX MX2019004539A patent/MX2019004539A/es unknown
- 2017-10-20 RU RU2019115303A patent/RU2766354C2/ru active
- 2017-10-20 SG SG10201912431XA patent/SG10201912431XA/en unknown
-
2019
- 2019-04-07 IL IL265869A patent/IL265869A/en unknown
- 2019-04-16 PH PH12019500843A patent/PH12019500843A1/en unknown
- 2019-04-17 MX MX2023001219A patent/MX2023001219A/es unknown
- 2019-04-17 CL CL2019001048A patent/CL2019001048A1/es unknown
- 2019-04-17 DO DO2019000102A patent/DOP2019000102A/es unknown
- 2019-05-21 CO CONC2019/0005169A patent/CO2019005169A2/es unknown
-
2022
- 2022-04-05 US US17/713,683 patent/US20220288183A1/en active Pending
- 2022-06-28 AU AU2022204585A patent/AU2022204585A1/en not_active Abandoned
- 2022-11-16 JP JP2022183528A patent/JP2023025066A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018012096A2 (es) | Proteínas de fusión gdf15 y usos de estas | |
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| JP2016034981A5 (pt) | ||
| EA201991442A1 (ru) | ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9 | |
| BR112016019068A2 (pt) | construto, vetor recombinante, composição farmacêutica, método de inibição de replicação viral ou expressão de uma sequência alvo em uma célula infectada com um vírus, polipeptídeo de sau cas9 recombinante, construto de sau cas9 recombinante, construto recombinante para expressão de um rna guia individual e kit | |
| BR112017017884A2 (pt) | switches transcricionais desencadeados por ligação e métodos de uso dos mesmos | |
| BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
| BR112015028666B8 (pt) | Composição detergente, método para produzir a mesma, método para a limpeza de um objeto e usos da composição | |
| BR112017019625A2 (pt) | udp-glicosiltransferases | |
| CO2018006947A2 (es) | Novedoso bacteriófago pas-mup-1 de pasteurella multocida y su uso para inhibir la proliferación de pasteurella multocida | |
| MX2020005458A (es) | Variantes de alfa-amilasa y polinucleotidos que codifican las mismas. | |
| BR112012033714A2 (pt) | polipeptídeo com atividade de acetil xilano esterase e seus usos. | |
| BR112018001121A2 (pt) | vetor recombinante do vírus orf (orfv), célula, composição, uso de um vetor recombinante de orfv, e, molécula de ácido nucleico | |
| BR112016011095A2 (pt) | Sequência de endolisina el188 modificada | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| BR112016011091A2 (pt) | sequência de endolisina kz144 modificada | |
| MY187334A (en) | Xylanase | |
| BR112019007796A2 (pt) | construção de vacina e seus usos contra infecções causadas por staphylococcus | |
| BR112017011621A2 (pt) | gene n?au resistente ao vírus do mosaico do tabaco e métodos de clonagem e suas aplicações | |
| BR112018073669A2 (pt) | proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso | |
| BR112017018966A2 (pt) | gene de resistência a míldio em kalanchoe | |
| BR112018003580A2 (pt) | molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante | |
| BR112017022715A2 (pt) | variante do polipeptídeo gal-1, ácido nucleico, composição farmacêutica, método para modular uma resposta imunológica e método para tratamento de um sujeito | |
| WO2014151687A3 (en) | Compositions and methods to treat aids | |
| NO20085201L (no) | Rekombinante novirhabdoviruser og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: SOCPRA SCIENCES ET GENIE S.E.C. (CA) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |